How can we achieve universal access to low-cost treatment for HIV?

Autor: Andrew M. Hill, Anton L. Pozniak

Publikováno v: Journal of Virus Eradication, Vol 2, Iss 4, Pp 193-197 (2016)

Mass production of low-cost antiretrovirals (ARVs) has already allowed over 17 million individuals to access treatment for HIV infection, mainly in low-income countries. It is possible to manufacture combination ARVs for $110 per person-year, using t

Externí odkaz: https://doaj.org/article/aa156c9bf93848ae8a3a7791f8b77b1e

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis

Autor: Sonya J. Snedecor, Richard Grove, David Kratochvil, Yogesh Punekar, Matthew Radford

Publikováno v: BMC Infectious Diseases
BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-14 (2019)

Background Network meta-analyses (NMAs) provide comparative treatment effects estimates in the absence of head-to-head randomized controlled trials (RCTs). This NMA compared the efficacy and safety of dolutegravir (DTG) with other recommended or comm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03084ba6d4377266d58807f345bb3be2
https://doi.org/10.1186/s12879-019-3975-6

How can we achieve universal access to low-cost treatment for HIV?

Autor: Hill AM; St Stephens AIDS Trust , Chelsea and Westminster Hospital , London , UK., Pozniak AL; St Stephens AIDS Trust , Chelsea and Westminster Hospital , London , UK.

Publikováno v: Journal of virus eradication [J Virus Erad] 2016 Oct 05; Vol. 2 (4), pp. 193-197. Date of Electronic Publication: 2016 Oct 05.